{"id":401,"date":"2020-07-27T09:54:53","date_gmt":"2020-07-27T09:54:53","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=401"},"modified":"2020-07-27T09:54:53","modified_gmt":"2020-07-27T09:54:53","slug":"26-july-2020-hydroxychloroquine-postexposure-therapy-with-hcq-did-not-prevent-sars-cov-2-disease","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/26-july-2020-hydroxychloroquine-postexposure-therapy-with-hcq-did-not-prevent-sars-cov-2-disease\/","title":{"rendered":"(26 July 2020) Hydroxychloroquine- Postexposure therapy with HCQ did not prevent SARS-CoV-2 disease"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p id=\"page-title\" class=\"highwire-cite-title\">A Cluster-Randomized Trial of Hydroxychloroquine as Prevention of Covid-19 Transmission and Disease<\/p>\n<p>https:\/\/www.medrxiv.org\/content\/10.1101\/2020.07.20.20157651v1<\/p>\n<p class=\"\">&nbsp;An open-label, cluster-randomized trial (NCT04304053) including asymptomatic contacts exposed to a PCR-positive Covid-19 case in Catalonia, Spain. Clusters were randomized to receive no specific therapy (control arm) or HCQ 800mg once, followed by 400mg daily for 6 days (intervention arm). The primary outcome was PCR-confirmed symptomatic Covid-19 within 14 days. The secondary outcome was SARS-CoV-2 infection, either symptomatically compatible or a PCR-positive result regardless of symptoms. Adverse events (AEs) were assessed up to 28 days. The analysis included 2,314 healthy contacts of 672 Covid-19 index cases identified between Mar 17 and Apr 28, 2020. A total of 1,198 were randomly allocated to usual care and 1,116 to HCQ therapy. There was no significant difference in the primary outcome of PCR-confirmed, symptomatic Covid-19 disease (6.2% usual care vs. 5.7% HCQ; risk ratio 0.89 [95% confidence interval 0.54-1.46]), nor evidence of beneficial effects on prevention of SARS-CoV-2 transmission (17.8% usual care vs. 18.7% HCQ). The incidence of AEs was higher in the intervention arm than in the control arm (5.9% usual care vs 51.6% HCQ), but no treatment-related serious AEs were reported. Postexposure therapy with HCQ did not prevent SARS-CoV-2 disease and infection in healthy individuals exposed to a PCR-positive case. Findings do not support HCQ as postexposure prophylaxis for Covid-19.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>A Cluster-Randomized Trial of Hydroxychloroquine as Prevention of Covid-19 Transmission and Disease https:\/\/www.medrxiv.org\/content\/10.1101\/2020.07.20.20157651v1 &nbsp;An open-label, cluster-randomized trial (NCT04304053) including asymptomatic contacts exposed to a PCR-positive Covid-19 case in Catalonia, Spain. Clusters were randomized to receive no specific therapy (control arm)&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/26-july-2020-hydroxychloroquine-postexposure-therapy-with-hcq-did-not-prevent-sars-cov-2-disease\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(26 July 2020) Hydroxychloroquine- Postexposure therapy with HCQ did not prevent SARS-CoV-2 disease&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[4,9],"tags":[10],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/401"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=401"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/401\/revisions"}],"predecessor-version":[{"id":402,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/401\/revisions\/402"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=401"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=401"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=401"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}